journal article·2026-05Open access

A Biomimetic Micro‐Nano System Maximizing ‘Active Transport and Retention’ Effect in Solid Tumors

Kaiyun Yang, Jiajia Su, Alan J. Davidson, Zimei Wu, Wenli Zhang

Small· Volume 22· Issue 25

Abstract

ABSTRACT The Active Transport and Retention (ATR) principle offers a new strategy to enhance tumor entry of nanodrugs via transcytosis. However, its application is limited by poor tumor‐homing, endothelial polarized efflux, and uncontrollable transcytosis of the nanodrug. Herein, we construct a bio‐mimetic micro‐nano system (PG@BAM‐L RC ) comprising nanoliposomes (L RC ) and berbamine (BAM) within platelet‐derived microcarrier (PG), leveraging PG's tumor‐homing ability and MMP‐9 responsive remodeling for tumor‐specific cargo release. Thereafter, BAM selectively promotes basal transendothelial transport of L RC toward the tumor by modulating apical recycling endosomes. While R8 promotes the cellular uptake, the arginine‐lysine‐lysine‐arginine‐cysteine (Cys) ligand facilitates Golgi‐targeted transendothelial transport of L RC, bypassing the endo‐lysosome pathway. Once inside tumor cells, furin‐mediated Cys‐cleavage halts transcytosis, yielding superior intracellular drug retention compared to the non‐cleavable Cys counterpart (L RC’ ). Four murine tumor models are established, demonstrating high heterogeneity in collagen density, vascularity, and EPR effects. An orthotopic pancreatic tumor, characterized by minimal EPR effect, is selected to demonstrate the ATR effect of PG@BAM‐L RC . PG@BAM‐L RC loaded with BAY‐872243 exhibits exceptional tumor accumulation and therapeutic outcome compared to L RC, PG@L RC without BAM, and PG@BAM‐L RC . Collectively, this study establishes PG@BAM‐L RC as a robust tumor‐targeting system leveraging the ATR mechanism while addressing tumor heterogeneity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy University of Auckland Auckland New Zealand

School of Pharmacy China Pharmaceutical University Nanjing P. R. China

Department of Molecular Medicine and Pathology University of Auckland Auckland New Zealand

Funding

China Scholarship Council · Cancer Society of New Zealand

References (47)

Show source-provided references
1. 10.1016/j.jconrel.2014.03.03010.1016/j.jconrel.2014.03.030 ↗
2. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
3. 10.1016/j.addr.2022.11444910.1016/j.addr.2022.114449 ↗
4. 10.1038/s44222-024-00203-310.1038/s44222-024-00203-3 ↗
5. 10.1038/s41565-023-01323-410.1038/s41565-023-01323-4 ↗
6. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
7. 10.1038/s44222-024-00154-910.1038/s44222-024-00154-9 ↗
8. 10.1038/s44222-024-00165-610.1038/s44222-024-00165-6 ↗
9. 10.1016/j.biomaterials.2020.11990210.1016/j.biomaterials.2020.119902 ↗
10. 10.1016/S0955-0674(00)00120-410.1016/S0955-0674(00)00120-4 ↗
11. 10.1016/j.addr.2007.06.00810.1016/j.addr.2007.06.008 ↗
12. 10.1016/j.addr.2022.11448010.1016/j.addr.2022.114480 ↗
13. 10.1021/acsnano.5b0558310.1021/acsnano.5b05583 ↗
14. 10.1002/adma.20170430710.1002/adma.201704307 ↗
15. 10.1016/j.jconrel.2023.01.02610.1016/j.jconrel.2023.01.026 ↗
16. 10.1016/j.jconrel.2022.09.03610.1016/j.jconrel.2022.09.036 ↗
17. 10.1182/blood-2004-08-298010.1182/blood-2004-08-2980 ↗
18. 10.3390/pharmaceutics1412261410.3390/pharmaceutics14122614 ↗
19. 10.1155/2022/259296210.1155/2022/2592962 ↗
20. 10.4048/jbc.2011.14.2.8810.4048/jbc.2011.14.2.88 ↗
21. Mechanisms of Receptor Shedding in Platelets
22. 10.1039/D0TB02848G10.1039/D0TB02848G ↗
23. 10.1002/psc.340810.1002/psc.3408 ↗
24. 10.1016/j.biomaterials.2016.01.06110.1016/j.biomaterials.2016.01.061 ↗
25. 10.1038/aps.2009.1910.1038/aps.2009.19 ↗
26. 10.1016/j.ejphar.2021.17467910.1016/j.ejphar.2021.174679 ↗
27. 10.1074/jbc.270.47.2839710.1074/jbc.270.47.28397 ↗
28. 10.1074/jbc.M70938720010.1074/jbc.M709387200 ↗
29. 10.1186/s40170-015-0138-010.1186/s40170-015-0138-0 ↗
30. 10.1208/s12249-019-1485-x10.1208/s12249-019-1485-x ↗
31. 10.2217/nnm-2018-051010.2217/nnm-2018-0510 ↗
32. 10.1016/j.mtbio.2022.10021210.1016/j.mtbio.2022.100212 ↗
33. 10.1371/journal.pone.004464010.1371/journal.pone.0044640 ↗
34. 10.1007/s00232-006-0080-810.1007/s00232-006-0080-8 ↗
35. 10.3390/molecules1310246210.3390/molecules13102462 ↗
36. VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer
37. 10.1186/s13058-017-0801-110.1186/s13058-017-0801-1 ↗
38. 10.1038/s41563-023-01630-010.1038/s41563-023-01630-0 ↗
39. 10.1097/00001721-199711000-0000610.1097/00001721-199711000-00006 ↗
40. 10.1038/s41388-018-0555-y10.1038/s41388-018-0555-y ↗
41. 10.1016/j.colsurfb.2017.07.01410.1016/j.colsurfb.2017.07.014 ↗
42. 10.1021/acsami.3c1023710.1021/acsami.3c10237 ↗
43. 10.1007/s11095-021-02988-z10.1007/s11095-021-02988-z ↗
44. 10.1021/acsami.6b0082110.1021/acsami.6b00821 ↗
45. 10.1016/B978-012372551-6/50066-310.1016/B978-012372551-6/50066-3 ↗
46. 10.1002/cam4.11210.1002/cam4.112 ↗
47. 10.1038/sj.bjp.070485210.1038/sj.bjp.0704852 ↗